The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study
MSD has revealed that the National Institute for Health and Care Excellence (NICE) has recommended the use of Keytruda.
Also known as pembrolizumab, the therapy treats tumours with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR). It also involves adults with advanced or recurrent endometrial cancer that has progressed during or after platinum-based therapy, as well as certain patients with gastric, small intestine or biliary cancer…
